TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
A study published Nov. 4 in Science Translational Medicine found that tau accumulated at more than twice the rate in people with early-onset Alzheimer’s as in older-onset patients. The findings may help explain differences in symptoms and progression, but the study did not test treatments or establish why tau changes faster.
A study comparing 601 people with Alzheimer’s disease found that tau, a protein associated with the condition, accumulated at more than twice the rate in patients whose symptoms began before age 65 than in patients whose symptoms began at 65 or later. Published Nov. 4 in Science Translational Medicine, the research may help explain why early-onset Alzheimer’s can progress faster and present with symptoms beyond memory loss, though it did not test treatments.
The researchers studied 390 early-onset patients in the Longitudinal Early-Onset Alzheimer’s Disease Study, whose average age was 59, and 211 late-onset patients in the Alzheimer’s Disease Neuroimaging Initiative, whose average age was 78. All participants had mild cognitive impairment or mild dementia attributed to Alzheimer’s, and PET scans showed amyloid accumulation, an early biomarker of the disease.
A subset of participants had repeat tau PET scans over an average of two to three years, allowing the research team to track changes. The study reported more extensive tau deposits and wider spread through the brain among people with early-onset disease. Differences between the age-of-onset groups were greater for tau than for amyloid, according to the report.
Among early-onset participants, one in five had a non-memory-dominant presentation. More than 99% of late-onset participants with documented presentations had memory-dominant symptoms. The study excluded people with known disease-causing mutations, the researchers said. It was supported by the U.S. National Institute on Aging.
Tau Patterns May Explain Symptom Differences
The findings point to a difference in the biology of Alzheimer’s by age of onset, not just a difference in when symptoms appear. More rapid tau accumulation and broader distribution could help account for the faster progression sometimes seen in early-onset disease, as well as symptoms involving language, visual and spatial abilities, or executive functioning. The study describes an association; it does not prove that tau changes alone cause those outcomes.
The distinction may also matter for treatment research. The two drugs approved to slow Alzheimer’s progression target amyloid, while the study found more pronounced differences between age groups in tau. Senior author Gil Rabinovici of the University of California, San Francisco, said the results raise the possibility that tau-targeting treatments could be particularly relevant for early-onset patients and that younger patients may be candidates for trials combining approaches against amyloid and tau. The research did not evaluate whether any such treatment works.
Products Worth Considering
Fitbit Inspire 3 Health and Fitness Tracker Bundle
Fitbit Versa 2 Health and Fitness Smartwatch with Heart Rate, Alexa, Music, Sleep and Swim Tracking
Oral-B iO Series 3 Rechargeable Electric Toothbrush for Adults, Black, 3 Modes, 2 Brush Heads and Travel Case
As an affiliate, we earn on qualifying purchases.
How Researchers Tracked Tau Over Time
Early-onset Alzheimer’s is defined in the study as symptoms beginning before age 65; late-onset disease begins at 65 or older. Early-onset cases make up about 5% of Alzheimer’s patients, according to the News-Medical report. People with the younger-onset form are more likely to have initial difficulties that do not center on memory.
Renaud La Joie, a UCSF co-senior author, described examples that can include trouble interpreting what a person sees despite a normal eye examination, judging distances, or reading. Some patients have difficulty finding words or following long sentences while remaining fluent; others experience changes in attention, planning, problem-solving, or adapting to situations. These examples describe possible presentations, not symptoms experienced by every patient.
The paper, by Chiotis and colleagues, is titled “Distinct tau PET dynamics in early versus late age-of-onset Alzheimer’s disease.” Its publication in Science Translational Medicine on Nov. 4, 2026, reports a comparison of patient groups using PET imaging. Repeat scans were available only for a subset, and the study’s findings concern tau patterns rather than treatment outcomes.
“We don’t fully understand why Alzheimer’s develops so early in some people.”
— Konstantinos Chiotis, first author
Causes and Treatment Effects Remain Unknown
The study found a difference in tau accumulation between age-of-onset groups, but it does not explain why tau changes more rapidly in younger patients. Chiotis said genetic factors beyond the known disease-causing mutations excluded from the study may warrant investigation. The findings also do not establish whether faster tau accumulation directly causes the differences in symptoms or progression.
Researchers did not test Alzheimer’s drugs or determine whether patients with early-onset disease respond differently to existing treatments. Repeat tau scans covered only a subset of participants, and the follow-up averaged two to three years. The report does not specify how representative the study groups are of all people with Alzheimer’s or provide a basis for predicting an individual patient’s course.
Genetic Studies and Tau Trials Ahead
The next steps raised by the findings include investigating whether genetic factors help explain the tau differences and testing whether treatments aimed at tau could benefit people with early-onset disease. Rabinovici said younger patients may be candidates for clinical trials combining amyloid- and tau-targeting treatments. Whether such trials will be conducted, and what outcomes they might show, was not established in the report.
For now, the study adds evidence about how Alzheimer’s biology may vary with age of onset. Its results are not treatment guidance and do not show that a particular therapy will slow tau accumulation. Further research will be needed to connect these imaging patterns with clinical outcomes and to determine whether they can inform treatment decisions.
Key Questions
What did the study find about tau in early-onset Alzheimer’s?
Researchers reported that tau deposits were more extensive and accumulated at more than twice the rate in early-onset patients than in late-onset patients in the study.
How did the researchers define early-onset Alzheimer’s?
The study classified Alzheimer’s as early-onset when symptoms began before age 65. Symptoms beginning at 65 or later were classified as late-onset.
Can early-onset Alzheimer’s affect abilities other than memory?
Yes. The report describes possible language, visual and spatial, and executive-function difficulties. These symptoms do not occur in every patient, and the study found that one in five early-onset participants had a non-memory-dominant presentation.
Does this study show that tau-targeting drugs work?
No. The research compared tau patterns using PET scans and did not test treatments. The authors said the results could inform future research, including trials combining amyloid- and tau-targeting approaches.
Why might tau findings matter for treatment research?
The study found age-of-onset differences were greater for tau than for amyloid, while the two drugs approved to slow Alzheimer’s progression target amyloid. Researchers said this may support investigating tau-targeting approaches, but their effectiveness remains untested by this study.
Source: news-medical.net
